Flexion Therapeutics Inc Form 8-K June 07, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 7, 2016

Flexion Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction

001-36287 (Commission

26-1388364 (IRS Employer

of incorporation)

File Number)

Identification No.)

Edgar Filing: Flexion Therapeutics Inc - Form 8-K

10 Mall Road, Suite 301

Burlington, Massachusetts 01803 (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (781) 305-7777

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

We are filing certain information for the purpose of updating the description of our risk factors contained in our other filings with the Securities and Exchange Commission. A copy of this additional disclosure is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits.

Exhibit

No. Description

99.1 Company disclosure.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Flexion Therapeutics, Inc.

Dated: June 7, 2016

By: /s/ Frederick Driscoll Frederick Driscoll Chief Financial Officer

INDEX TO EXHIBITS

Exhibit No. Description

99.1 Company disclosure.